AAV vector manufacturing market set to grow at ~22% CAGR, reaching $5.2B by 2034 driven by gene therapy demand.

The global AAV vector manufacturing market is projected to expand at a compound annual growth rate (CAGR) of approximately 22% from 2026 to 2034, reaching a market size of $5.2 billion by 2034. This growth is fueled by increasing gene therapy research and development, rising prevalence of genetic and rare diseases, and advancements in manufacturing technologies. North America currently leads the market, supported by regulatory approvals and clinical trials, while Asia-Pacific and Europe also show strong growth due to expanding gene therapy pipelines and supportive regulations. Key players include Thermo Fisher Scientific, Catalent Gene Therapy, and Lonza Group among others. The market is further boosted by investments, outsourcing trends, and technological innovations enhancing production efficiency and scalability.